Work

Correction to Lancet Infect Dis 2026; published online Jan 23. https://doi.org/10.1016/S1473-3099(25)00730-3

Year: 2026

Type: erratum

Abstract: De Coster I, AbdelGhany M, Sarakinou E, et al. Safety and immunogenicity of a conjugate vaccine candidate against Salmonella enterica serovars Typhi and Paratyphi A in healthy adults in Europe: a phase 1 randomised controlled trial. Lancet Infect Dis 2026; published online Jan 23. https://doi.org/10.1016/S1473-3099(25)00730-3—In the Acknowledgments of this Article, the funding statement should have been “This work was funded by the Wellcome Trust [089102/Z/09/Z] and this publication was sponsored by GSK.” This correction has been made to the online version as of Feb 4, 2026, and will be made to the printed version.

Source: The Lancet Infectious Diseases

DOI: 10.1016/s1473-3099(26)00066-6

Language: English

Topic: Salmonella and Campylobacter epidemiology

Subfield: Food Science

Field: Agricultural and Biological Sciences

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $7,280

Funders: Wellcome Trust, GlaxoSmithKline Biologicals

Award: Conjugate vaccine that protects against typhoid fever caused by the Salmonella enterica serovars Typhi and Paratyphi A.

OpenAlex ID: W7127601370

Cites:

Cited by:

Related to: